<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548973</url>
  </required_header>
  <id_info>
    <org_study_id>MZK20200831</org_study_id>
    <nct_id>NCT04548973</nct_id>
  </id_info>
  <brief_title>A Multicenter Study of the Efficacy and Safety of Esketamine for Analgesia During Cesarean Section</brief_title>
  <official_title>A Multicenter Study of the Efficacy and Safety of Esketamine for Analgesia During</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Women's Hospital School Of Medicine Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposed applying intravenous Esketamine to cesarean section in parturient,&#xD;
      detecting the plasma concentration of Esketamine in maternal blood, neonatal umbilical venous&#xD;
      blood and umbilical arterial blood when the baby is delivered ketamine blood drug&#xD;
      concentration, observing vital signs, adverse visual analog pain score (VAS), and sedation&#xD;
      score (Ramsay) in parturient, neonatal Apgar score 1, 5 to 10 minutes after birth, the&#xD;
      umbilical arterial blood gas and neurobehavioral scores (NBNA) 2, 24 hours after the birth.&#xD;
      This study aims to address placental transfer, metabolism and analgesic and sedative effects&#xD;
      in neonates and parturients of Esketamine so as to explore the feasibility, efficacy and&#xD;
      safety of Esketamine as adjuvant medication for cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. case selection: A total of 600 patients (American Society of Anesthesiologists (ASA)&#xD;
           grade I-II, aged 20-40 years,BMI 18.5-27) who underwent elective cesarean section were&#xD;
           selected.&#xD;
&#xD;
        2. anesthesia methods: All patients were not given preoperative medication. After entering&#xD;
           the operating room, peripheral venous connection was opened. Mindray multifunctional&#xD;
           vital sign monitor continuously monitored electrocardiogram (ECG), heart rate (HR),&#xD;
           pulse oxygen saturation (SpO2), systolic blood pressure (SBP), diastolic blood pressure&#xD;
           (DBP) and Mean arterial pressure (MAP). After 5 minutes of waiting for patients with no&#xD;
           obvious discomfort, 0.75% of ropivacaine was given 10ml before catheterization, and&#xD;
           0.75% of ropivacaine 3-5ml per hour maintained anesthesia&#xD;
&#xD;
        3. Grouping methods: A random number table was used to divide the patients into two groups&#xD;
           with 300 patients in each group: The Esketamine group (group A) and the control group&#xD;
           (group B) Esketamine group (Group A): at the beginning of the operation, 0.25mg/kg(2ml)&#xD;
           Esketamine was administered intravenously as an adjuvant sedation and analgesia;Control&#xD;
           group (Group B): 2ml normal saline was given intravenously at the beginning of the&#xD;
           operation;&#xD;
&#xD;
        4. Observation items and methods 4.1 Forty patients were randomly selected from the&#xD;
           Estroketamine group (group A) to detect the serum concentrations of Esketamine in&#xD;
           umbilical vein blood and umbilical artery blood of neonates during fetal delivery.&#xD;
&#xD;
      4.2 maternal hemodynamic indexes such as heart rate (HR), mean arterial pressure (MAP) and&#xD;
      respiratory mechanics indexes such as pulse oxygen saturation (SpO2) and shout at the end of&#xD;
      the co2 partial pressure (PaCO2) are measured before anesthesia surgery at the beginning of&#xD;
      the fetal childbirth at the end of the operation and operation after 1 hour when recording&#xD;
      and compare the two groups of 4.3 maternal visual analog pain score (VAS) and sedation scores&#xD;
      (Ramsay) and the time from uterine incision to fetal childbirth are measured before&#xD;
      anesthesia surgery at the beginning of the fetal childbirthAt the end of the operation and&#xD;
      operation after 1 hour record and compare the two groups of 4.4 respiratory system&#xD;
      complications within 72 h in pregnant women (hypotension sinus bradycardia nausea and&#xD;
      vomiting respiratory depression) are record.&#xD;
&#xD;
      4.5 Apgar score 1, 5, 10 minutes after birth, umbilical arterial blood gas and&#xD;
      neurobehavioral scores (NBNA) 2 and 24 hours after the birth are record.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analog pain score (VAS), and sedation score (Ramsay)</measure>
    <time_frame>At the beginning of the operation, before anaesthesia, at the end of the operation, and 1 hour after the operation</time_frame>
    <description>visual analog pain score (VAS), and sedation score (Ramsay)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Fetal or Neonatal Effect of Damage to Placenta From Caesarean Section</condition>
  <arm_group>
    <arm_group_label>Esketamine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the beginning of the operation, 0.25mg/kg ketamine was administered intravenously, and normal saline was diluted to 2mL to assist sedation and analgesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At the beginning of the operation, 2ml normal saline was given intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>Esketamine</description>
    <arm_group_label>Esketamine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>2ml normal saline</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Women who had no preoperatie electrolyte disturbance and immunoendocrine&#xD;
        disease and who had not recently receied cardiovascular nonsteroidal anti-inflammatory&#xD;
        drugs, hormone drugs or antipsychotic drugs -&#xD;
&#xD;
        Exclusion Criteria:Parturient women with central nervous system disease, liver disease,&#xD;
        renal dysfunction, cardiopulmonary dysfunction, diabetes, severe hypovolemia, preeclampsia&#xD;
        and eclampsia&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>parturient</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esketamine, cesarean section, parturient, placental transfer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

